Europe — EMA

Omvoh (Mirikizumab)

Mirikizumab, the active ingredient in Omvo, is a monoclonal antibody presented as a unknown strength/unknown form for subcutaneous injection use. It treats moderate to severe ulcerative colitis in adult patients.

Mirikizumab

Request sourcing

Pack/s

What is Mirikizumab?

GNH USA supplies Omvo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide worldwide.

What is Mirikizumab used for?

Omvo ... ... .... ... ... ... … … ... .... ... ... ... ...

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →